Bio-Rad Laboratories (BIO-B) Net Cash Flow (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Net Cash Flow data on file, last reported at -$29.1 million in Q1 2026.

• Quarterly Net Cash Flow fell 182.91% year-over-year to -$29.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.9 million (down 105.79% YoY) and the FY2025 annual result came in at $59.3 million, down 22.18% from the prior year.
• Net Cash Flow retreated to -$29.1 million in Q1 2026 per BIO-B's latest filing, from $134.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $324.7 million in Q1 2022 and bottomed at -$212.5 million in Q2 2022.
• The 5-year median for Net Cash Flow is $11.9 million (2024), against an average of $2.1 million.
• Peak annual rise in Net Cash Flow reached 1710.06% in 2022, while the deepest fall reached 471.66% in 2022.
• Tracing BIO-B's Net Cash Flow over 5 years: stood at -$65.5 million in 2022, then grew by 27.71% to -$47.4 million in 2023, then soared by 242.47% to $67.5 million in 2024, then surged by 98.52% to $134.0 million in 2025, then plunged by 121.72% to -$29.1 million in 2026.
• Per Business Quant, the three latest BIO-B Net Cash Flow figures stand at -$29.1 million (Q1 2026), $134.0 million (Q4 2025), and $25.4 million (Q3 2025).

Peer Comparison